FDA approves first treatment to reduce risk of serious heart problems specifically in adults with obesity or overweight

The U.S. Food and Drug Administration recently approved a new indication for use for Wegovy (semaglutide) injection to reduce the risk of cardiovascular death, heart attack and stroke in adults with cardiovascular disease and either obesity or overweight. 

Related Keywords

United States ,American ,Novo Nordisk ,John Sharretts ,Division Of Diabetes ,Drug Administration ,Lipid Disorders ,Drug Evaluation ,Multiple Endocrine Neoplasia ,Priority Review ,